Abstract:e21123 Background: Upregulation of CD73 results in the adenosine overproduction, which suppresses immune responses in tumoral microenvironment. Uliledlimab (ULI), a differentiated anti-CD73 antibody, inhibits adenosine generation in a non-competitive manner and suppresses tumor growth when combined with a PD-(L)1 inhibitor. Methods: The dose-escalation and dose expansion phase I/II study (NCT04322006) was designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ULI alone, or combined with toripalimab (TOR) in patients with advanced solid tumor. ULI was administered iv. at 2, 5,10 mg/kg weekly (QW) or at 15, 20, 30 mg/kg every 3 weeks (Q3W) alone, or combined with TOR (240 mg, iv, Q3W) in dose escalation. Preliminary efficacy of ULI (20 mg/kg Q3W) + TOR (240 mg Q3W) was examined in non-small cell lung cancer (NSCLC) in dose expansion cohorts. Serum concentration of ULI and soluble CD73, CD73 receptor occupancy (RO) in circulating CD19 + B cells were detected. Tumor response was assessed by RECIST1.1/iRECIST. Results: As of 12/5/2021, a total of 92 patients were enrolled: 12 in dose escalation of ULI alone, 9 in ULI+TOR dose escalation group, and 71 in ULI+TOR dose expansion cohorts. ULI was well-tolerated with no DLT observed in dose escalation. Most of treatment-related adverse event (TRAE) were grade 1-2 with grade 3-4 TRAE occurring in 2 patients with decreased lymphocyte count and 1 with transient QT prolongation in ULI monotherapy group, and 2 patients each with hypotension and diarrhea as most reported events in ULI+TOR group. Most common TRAE were grade 1-2 chills (47.8%), vomiting (46.7%), pyrexia (40.2%), diarrhea (32.6%), nausea (19.6%), pruritus (14.1%), rash (13%) that occurred after the first dose of ULI and resolved in subsequent infusions, which can be significantly reduced by steroid-based premedication. The PK of ULI was linear at doses ≥ 5 mg/kg and modelling indicated a mean derived effective t 1/2 of ̃13.2 days. Soluble CD73 was undetectable and complete RO was maintained after the first dose at ≥ 15 mg/kg Q3W at C trough throughout the dosing interval. As of 12/13/2021, among 48 efficacy-evaluable NSCLC patients in dose expansion cohorts, 6 partial responses (PR) (ORR 12.5%, 95%CI: 4.7%-25.2%) and 21 stable diseases (DCR 56.4%, 95%CI, 41.2%-70.5%) were observed. PRs were observed in 3 out of 8 systematic treatment-naïve patients, and 3 out of 39 patients with relapse/refractory disease to previous systematic treatment including 2 patients received no prior PD-(L)1 inhibitor treatment and 1 patient failed pembrolizumab. Conclusions: ULI was safe and tolerated up to 30 mg/kg Q3W. Linear PK observed at doses ≥ 5 mg/kg with t 1/2 of 13.2 days. Full saturation of circulating and cell-bound CD73 was maintained at doses ≥ 15 mg/kg Q3W. ULI combined with TOR exhibited evidence of anti-tumor activity in NSCLC patients. Clinical trial information: NCT04322006.

A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors

Evaluation of toxicity and single-dose pharmacokinetics of intravenous ursolic acid liposomes in healthy adult volunteers and patients with advanced solid tumors.

A Phase I Pharmacokinetic Study of Ursolic Acid Nanoliposomes in Healthy Volunteers and Patients with Advanced Solid Tumors

A Phase I Clinical Trial of Ursolic Acid Nanoliposome for Evaluating Its Single-Dose Tolerance and Safety

Original Article Utidelone-based Therapy in Advanced or Metastatic Solid Tumors after Failure of Standard Therapies: a Prospective, Multicenter, Single-Arm Trial

Safety, efficacy, pharmacokinetics of uliledlimab alone or combined with toripalimab in advanced solid tumor: Initial results of a phase I/II study.

Phase I Study Results of APG-115, a MDM2-p53 Antagonist in Chinese Patients with Advanced Liposarcoma and Other Solid Tumors.

Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma

Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study

Phase I Dose-Escalation Study of Chiauranib, a Novel Angiogenic, Mitotic, and Chronic Inflammation Inhibitor, in Patients with Advanced Solid Tumors

Ursolic Acid Derivative UA232 Promotes Tumor Cell Apoptosis by Inducing Endoplasmic Reticulum Stress and Lysosomal Dysfunction

Solubilization and Delivery of Ursolic-acid for Modulating Tumor Microenvironment and Regulatory T Cell Activities in Cancer Immunotherapy.

A Phase Ia/Ib Study of CBP-1008, a Bispecific Ligand Drug Conjugate, in Patients with Advanced Solid Tumors

Synthesis and Evaluation of Ursolic Acid Derivatives As Potent Cytotoxic Agents.

Synthesis and Biological Evaluation of Novel Ursolic acid Derivatives as Potential Anticancer Prodrugs

Primary Analysis of a Phase 1/2 Study of LM-101: an Anti-Sirpα Antibody As a Single Agent in Patients with Advanced Malignancies.

A Single-Arm, Multicenter, Phase II Study of Utidelone in Advanced Solid Tumors: Efficacy Data from Screening and the Expansion Cohort Assessing Utidelone Plus Sintilimab and Oxaliplatin for Advanced Gastric Cancer.

A phase I study to evaluate the safety, tolerability, and pharmacokinetics of MSB0254 in Chinese patients with solid tumors.

Synthesis of [3Β-Acetoxy-urs-12-en-28-oyl]-1-monoglyceride and Investigation on Its Anti Tumor Effects Against BGC-823.

Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.

Abstract P4-01-07: FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study